TCIIS
FATE icon

TIAA-CREF Individual & Institutional Services’s Fate Therapeutics FATE Stock Holding History

TIAA-CREF Individual & Institutional Services’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.5K Hold
17,592
– – ﹤0.01% 742
2026
Q1 		$21.1K Buy
+17,592
New +$21.4K ﹤0.01% 701

Other funds holding FATE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

TIAA-CREF Individual & Institutional Services's FATE Position: Q2 2026 in Review

TIAA-CREF Individual & Institutional Services held its Fate Therapeutics (FATE) position steady in Q2 2026 at 17,592 shares worth $47.5K. The position accounts for ﹤0.01% of the portfolio, ranked #742.

TIAA-CREF Individual & Institutional Services first reported a position in FATE in Q1 2026 and has held it in 2 quarters since. 141 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • TIAA-CREF Individual & Institutional Services held 17,592 shares of Fate Therapeutics worth $47.5K as of Q2 2026.
  • TIAA-CREF Individual & Institutional Services left its Fate Therapeutics share count unchanged in Q2 2026.
  • Fate Therapeutics made up ﹤0.01% of TIAA-CREF Individual & Institutional Services's portfolio in Q2 2026, its #742 holding.
  • TIAA-CREF Individual & Institutional Services first reported a position in Fate Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 141 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on TIAA-CREF Individual & Institutional Services's 13F filing for Q2 2026, filed 10 Aug 2026.